The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program

PD-L1 is a proven biomarker for patient response to KEYTRUDA® (pembrolizumab) in esophageal squamous cell carcinoma (ESCC) (PD-L1 IHC 22C3 pharmDx [Instructions for Use], 2022). Review how to evaluate and score PD-L1 expression using PD-L1 IHC 22C3 pharmDx and the Combined Positive Score (CPS).

The Dako PD-L1 IHC 22C3 pharmDx Interpretation Training Program uses in-depth content, engaging activities, and comprehensive cases to help you confidently:

  • Understand the core principles of PD-L1 pathology
  • Learn the process for evaluating stained specimens for PD-L1 expression
  • Recognize confounding considerations that affect PD-L1 interpretation
  • Score images for PD-L1 expression across a variety of patient samples
Review the PD-L1 IHC 22C3 pharmDx Intended Use
For countries outside of the United States, see the local KEYTRUDA product label for approved indications and expression cutoff values to guide therapy.

Get started

REGISTER NOW
Already registered? LOGIN NOW